Company intelligence / Profile preview

Economic Development Generating Excellence

Berkeley Heights, New Jersey, United Statesedgetherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Edge Therapeutics was a clinical-stage biotechnology company focused on developing innovative hospital-based therapies for life-threatening neurological conditions. The company's lead product candidate, EG-1962, was a sustained-release microparticle formulation of nimodipine designed to prevent delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage. Edge utilized its proprietary Precisa platform to deliver therapeutic agents directly to the site of injury, aiming to improve efficacy while reducing systemic side effects. In 2019, the company completed a strategic merger with PDS Biotechnology Corporation.

Therapeutic areas: Neurology
Modalities: Small moleculeMicroparticle
Industry: Biotech

Beyond the preview

Go deeper on Economic Development Generating Excellence.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Economic Development Generating Excellence.

Explore the full profile